Sign In
Last checked at 
12 Jan 2011 17:14
Hikma Pharmaceuticals PLC - Voting Rights and Capital
LONDON, 12 January 2011 Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) notifies the market that as at 31 December 2010 its capital consists of 193,516,989 ordinary shares with voting rights. There are no shares held in treasury.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under the FSA's Disclosure and Transparency Rules.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC | |
Henry Knowles Company Secretary
| +44 20 7399 2760
|
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2009, Hikma achieved revenues of $637 million and profit attributable to shareholders of $78 million. For news and other information, please visit www.hikma.com.
Follow the stocks
